1. Introduction {#s0005}
===============

Social anxiety disorder (SAD) is one of the most common anxiety disorders ([@bb0410]), with an estimated lifetime prevalence between 6 and 13 percent ([@bb0225], [@bb0415]). Patients with SAD are characterized by intense fear of, distress in, and avoidance of situations in which they may be scrutinized ([@bb0010]). The disorder is highly disabling, as impairments in social life and work situations are frequently reported ([@bb0265]). In addition, the disorder is associated with significant psychiatric co-morbidity, such as depressive disorders and substance abuse ([@bb0410]). These findings stress the need for improvements in the treatment of SAD. Understanding the neurobiological mechanisms that underlie this disorder has the potential to advance treatment.

Previous magnetic resonance imaging (MRI) studies on brain anatomy differences in SAD have reported heterogeneous findings, implicating regions such as the frontal cortex, the parietal cortex, occipital cortex, temporal regions and subcortical limbic areas, as reviewed by [@bb0070]; see also [@bb0170] reporting on a transdiagnostic meta-analysis of structural neuroimaging studies. Several of these changes were correlated with clinical characteristics, such as the severity of social anxiety symptoms ([@bb0075], [@bb0130], [@bb0210], [@bb0205], [@bb0255], [@bb0420], [@bb0425], [@bb0455]) or disease duration ([@bb0290]). In addition, recent treatment studies in SAD-patients have identified structural changes in bilateral caudate and putamen, right thalamus and cerebellum after 8-weeks of paroxetine treatment ([@bb0430]) and alterations in parieto-occipital and prefrontal GM volumes after cognitive behavioral group therapy ([@bb0405]), while a classification study using multi-voxel pattern analysis was able to discriminate SAD-patients from healthy control participants based on the pattern of regional gray matter (GM) volume over the whole brain ([@bb0135]). Together, these studies provide evidence for the idea that certain brain regions are clinically associated with SAD.

Functional MRI (fMRI) studies have also identified important candidate brain regions that may be related to structural changes associated with SAD-related psychopathology. These fMRI studies, typically examining brain activity in response to emotional stimuli or in response to cognitive tasks ([@bb0070]), most consistently point towards an increase of brain activation in SAD in the bilateral amygdala and hippocampus, prefrontal brain regions, bilateral insula, bilateral parietal cortex and bilateral precuneus, while findings on the direction of changes in the basal ganglia are mixed ([@bb0070], [@bb0100]). In addition, studies on functional connectivity, during rest as well as during cognitive tasks ([@bb0070]), revealed changes in connectivity of, among others, the putamen ([@bb0110]) and the amygdala ([@bb0175], [@bb0310], [@bb0380]), while recent positron emission tomography (PET) studies showed decreased serotonin receptor binding ([@bb0240]) and increased serotonin synthesis and transporter availability in the hippocampus, amygdala, anterior cingulate cortex (ACC) and striatal regions like the putamen and globus pallidus ([@bb0140], [@bb0145]). These results, together with the findings of a treatment study revealing a relationship between changes in amygdala structure and amygdala function in SAD ([@bb0280]), suggest that the brain regions showing functional changes in SAD overlap to a large extent with the regions that have showed differences in brain structure.

However, the available evidence with respect to structural brain alterations in SAD is inconclusive, as both increases as well as decreases in GM volumes in various brain regions have been reported ([@bb0070]). Furthermore, findings concerning the relationship between brain structure and SAD-symptoms are inconsistent ([@bb0075], [@bb0130], [@bb0210], [@bb0455]). These heterogeneous results are possibly due to differences in the employed methods, as well as the relatively small sample sizes employed in studies on SAD-related changes in brain structure (ranging from 12 to 67 SAD-patients), and variability in clinical parameters between the samples. Recent advances in multi-site imaging offer new opportunities to investigate the structural brain alterations associated with SAD.

In this international multi-center mega-analysis, which is part of the European and South African Research Network in Anxiety Disorders (EURSANAD) program initiated by the Anxiety Disorders Research Network ([@bb0030]), we investigated GM volume in a-priori defined regions of interest (ROIs) in a sample of 174 SAD-patients and 213 healthy control participants, using an optimized voxel-based morphometry (VBM) protocol ([@bb0025], [@bb0245]). VBM analyses have the advantage of using unbiased, standardized methods to investigate brain structure, and have been extensively used to investigate alterations in brain morphology across numerous major psychiatric conditions ([@bb0025], [@bb0170]). The large sample of the present work provides the best statistical power to date to investigate GM alterations associated with SAD. Data were collected in multiple scan centers located in five countries (Germany, South Africa, Sweden, the Netherlands and the United States of America). Based on the available evidence reviewed above, our analysis focused on changes in GM volume in four a-priori defined ROIs that seem to be most prominently involved in SAD: the basal ganglia, the amygdala-hippocampal complex, the prefrontal cortex and the parietal cortex including the precuneus. Given the mixed findings on SAD-related increases versus decreases in GM in the previous structural MRI studies ([@bb0070]), we did not make specific predictions about the direction of the changes within these ROIs. Significant results within the ROIs were followed up by regression analyses to investigate the relationship between GM volumes and the severity of social anxiety symptoms within the patient group.

2. Material and methods {#s0010}
=======================

2.1. Participants {#s0015}
-----------------

Structural T1-weighted 3T MRI scans were collected at research centers located in Europe, Africa and North-America, and brought together for quality control and initial analysis in Cape Town, South-Africa. Final analyses took place in Leiden, the Netherlands. The initial sample consisted of 251 SAD-patients and 230 healthy control (HC)-participants ([Table 1](#t0005){ref-type="table"}), and results on these datasets have been published previously ([@bb0065], [@bb0055], [@bb0060], [@bb0105], [@bb0155], [@bb0195], [@bb0230], [@bb0275], [@bb0270], [@bb0310], [@bb0330], [@bb0420], [@bb0445]) -- see [Inline Supplementary Document 1](#ec0005){ref-type="supplementary-material"} for more details on the in- and exclusion criteria and recruitment of participants for each sample. At each site, the local ethical committee approved data-collection and all participants provided written informed consent after the procedure had been fully explained.

Participants (18 years or older) were recruited through public announcements (online and within the community), consumer advocacy groups, general practitioners and clinical centers, and screened using structured clinical interviews in their native language: the Mini-International Neuropsychiatric Interview ([@bb0370]), the Composite Interview Diagnostic Instrument version ([@bb0220]) or the Structured Clinical Interview for DSM-IV disorders ([@bb0120]). SAD-patients had to meet criteria for a primary diagnosis of SAD, while HC-participants had to be free of any psychopathology. General MRI contraindications (ferromagnetic implants, claustrophobia, pregnancy) were a reason for exclusion in both groups.Table 1Sample composition.Table 1**Initial number of scansExcluded number of scansIncluded number of scansCountryResearch centerSADHCComorbidity**[a](#tf5005){ref-type="table-fn"}**Insufficient scan-quality**[b](#tf5010){ref-type="table-fn"}**Brain pathologyOther reason**[c](#tf5015){ref-type="table-fn"}**SADHCTotalGermany** ([@bb0065], [@bb0055], [@bb0060])University of Jena; University of Münster5322313001922**41The Netherlands (**[@bb0315], [@bb0310], [@bb0320], [@bb0445]), ([@bb0105])VU Medical Center Amsterdam - NESDA Study10271300627**33**University of Groningen - NESDA Study9121100811**19**Leiden University Medical Center - NESDA Study9261000826**34**Leiden University Medical Center - Social Anxiety Study202000002020**40South-Africa** ([@bb0155], [@bb0195], [@bb0420])University of Cape Town; Stellenbosch University1817210001211**23Sweden** ([@bb0275], [@bb0270])Umeå University262603002623**49**Uppsala University2400002400**0United States of America** ([@bb0230], [@bb0330])University of Chicago272534002421**45**University of Illinois121210001211**23**University of Michigan434323103941**80Total2512304227124174213387**[^2][^3][^4][^5]

In addition to the T1-weighted 3T MRI scans, demographic (age, gender, handedness) and clinical data were collected at each research center. Furthermore, information about education level, comorbidity, medication use and the scores on several questionnaires (Liebowitz Social Anxiety Scale (LSAS) ([@bb0185]), Beck Depression Inventory (BDI) ([@bb0045]) and State-Trait Anxiety Inventory (STAI) ([@bb0395])) were available for a subset of participants.

2.2. Data acquisition, quality checks and final sample {#s0020}
------------------------------------------------------

Parameters of the T1-weighted MRI scans are presented in [Table 2](#t0010){ref-type="table"}. Scans from SAD-patients with comorbid psychopathology other than any other anxiety disorder or major depressive disorder (MDD) were excluded from the analysis (*n* = 42, see [Table 1](#t0005){ref-type="table"} and [Inline Supplementary Table 1](#ec0010){ref-type="supplementary-material"}). Next, scans were extensively checked for pathology and quality, leading to the exclusion of an additional 28 scans ([Table 1](#t0005){ref-type="table"}). Furthermore, all scans from the research center in Uppsala (*n* = 24 SAD-patients) were excluded due to the lack of scans from HC-participants from this center, necessary for our analytic approach. This resulted in a final sample of 174 SAD-patients and 213 HC-participants. Characteristics of the final sample are presented in Table 3. Statistical analyses on differences between groups were performed using IBM SPSS Statistics (Version 23), with a significance level of *p* \< 0.05.Table 2Characteristics of T1-weighted MRI scans.Table 2**CountryResearch site/sampleScannerVoxelsDimensionsGermany**University of Jena; University of MünsterSiemens/TrioTim 3T192 × 256 × 2561 × 1 × 1 mm**The Netherlands**VU Medical Center Amsterdam - NESDA studyPhilips 3T170 × 256 × 2561 × 1 × 1 mmUniversity of Groningen - NESDA studyPhilips 3T170 × 256 × 2561 × 1 × 1 mmLeiden University Medical Center - NESDA studyPhilips 3T170 × 256 × 2561 × 1 × 1 mmLeiden University Medical Center - Social Anxiety StudyPhilips 3T256 × 256 × 1400.875 × 0.875 × 1.2 mm**South-Africa**University of Cape Town; Stellenbosch UniversitySiemens Magnetom Allegra 3T128 × 256 × 2561.33 × 1 × 1 mm**Sweden**Umeå UniversityGeneral Electric 3T512 × 512 × 1760.48 × 0.48 × 1 mmUppsala UniversityPhilips Achieva 3T480 × 480 × 1700.5 × 0.5 × 1 mm**United States of America**University of ChicagoGE Signa System 3T256 × 256 × 1200.94 × 0.94 × 1.5 mmUniversity of IllinoisGE Signa System 3T256 × 256 × 1820.86 × 0.86 × 1 mmUniversity of MichiganGE Signa System 3T256 × 256 × 1241 × 1 × 1.2 mm

2.3. Voxel-based morphometry analysis {#s0025}
-------------------------------------

Voxel-wise GM volumes were investigated using an optimized voxel-based morphometry (VBM) protocol, using the default pipeline as implemented in FSL (version 5.0.7) ([@bb0165], [@bb0390]). Structural T1-weighted images were first brain-extracted using FSL and Freesurfer software. Each brain was closely visually inspected and brain-extraction was repeated until all non-brain tissue was properly removed from the image. Subsequently, images were segmented into GM, white matter (WM) and cerebrospinal fluid (CSF) ([@bb0470]). Next, a study-specific GM template was created, in order to avoid biases during registration that could favour either the SAD or HC-group ([@bb0165]), by randomly selecting GM images from an equal number of SAD-patients and HC-participants from each research center (*n* = 166 SAD-patients and 166 HC-participants). These GM images were non-linearly registered to the Montreal Neurological Institute (MNI) T1-template brain, averaged and flipped along the x-axis to create a left-right symmetric study-specific GM template with a resolution of 2 × 2 × 2 mm. Subsequently, the original GM images from all participants were non-linearly registered to this template ([@bb0015]), modulated to correct for local expansion or contraction and smoothed using a kernel with an isotropic Gaussian kernel (σ = 3 mm).

2.4. Region of interest (ROI) analysis: differences between groups {#s0030}
------------------------------------------------------------------

In order to maximize the statistical power to detect GM differences between SAD-patients and HC-participants, we used a region of interest (ROI) approach ([@bb0335]) focusing on brain areas in which functional and structural brain changes related to SAD have been reported previously (see Introduction). Four ROIs were created in standard space (resolution 2 × 2 × 2 mm) using the Harvard-Oxford Cortical Structural Atlas and Harvard-Oxford Subcortical Structural Atlas implemented in FSLView (version 3.2.0). The *basal ganglia ROI* consisted of voxels with a probability of at least 50% of belonging to the bilateral accumbens, caudate, pallidum or putamen (total size of ROI: 3224 voxels, 25,792 mm^3^). The second ROI, the *amygdala-hippocampus ROI*, consisted of voxels with a probability of at least 50% of belonging to the bilateral amygdala, hippocampus and the anterior and posterior parahippocampal gyrus (total size of ROI: 3066 voxels, 24,528 mm^3^). The *prefrontal cortex ROI* included voxels with a probability of at least 50% of belonging to the middle frontal gyrus, the subcallosal cortex, the anterior cingulate gyrus, paracingulate gyrus, frontal medial cortex and frontal orbital cortex (total size of ROI: 20,601 voxels, 164,808 mm^3^). Finally, the *parietal ROI* encompassed voxels with a probability of at least 50% of belonging to the superior parietal lobule, the precuneus cortex and the posterior cingulate gyrus (total size of ROI: 5478 voxels, 43,824 mm^3^).

Within these ROIs, we examined differences in GM volume between SAD-patients and HC-participants using a general linear model (GLM). In this model, scan center (coded by dummy variables) and gender were added as nuisance regressors and age and total GM volume were included as covariates. Before we analyzed this GLM, we tested *the homogeneity of regression slopes assumption* that applies to covariate analysis, by building a separate GLM that included a diagnosis-by-age and a diagnosis-by-total GM regressor in addition to the other regressors. No significant interactions at the whole-brain level were observed, thus justifying the use of the abovementioned GLM that investigated the effect of diagnosis while correcting for the covariates.

Voxelwise statistics were applied using permutation-based non-parametric testing (5000 permutations), correcting for multiple comparisons across space. FSL\'s default threshold-free cluster enhancement (TFCE) was used to detect significant clusters ([@bb0385]) and we used a familywise error (FWE)-corrected threshold of *p* \< 0.05 within each ROI. Given the fact that ROIs were a priori defined and are part of a network of brain areas involved in SAD ([@bb0070]), we report *p*-values uncorrected for the number of ROIs. Significant results within the ROIs were followed up by a multiple regression analysis using IBM SPSS Statistics, in order to examine the relationship between average individual GM volume in the extracted cluster and the severity of total social anxiety symptoms (measured with the LSAS), while controlling for scan center, gender, age and total GM volume. In line with previous work ([@bb0130], [@bb0210], [@bb0290], [@bb0420]), this analysis was performed in SAD-patients only.

For reasons of completeness, we also performed an exploratory whole-brain VBM analysis to examine a main effect of diagnosis and interactions with age and scan center outside the predefined ROIs using the same GLM. Again, we used TFCE-results based on an FWE-corrected threshold of *p* \< 0.05.

3. Results {#s0035}
==========

3.1. Sample characteristics {#s0040}
---------------------------

Characteristics of SAD-patients (*n* = 174) and HC-participants (*n* = 213) are presented in [Table 3](#t0015){ref-type="table"}. SAD-patients did not differ from HC-participants in terms of age, gender, level of education, handedness and total GM volume, but they reported significantly more social anxiety symptoms (measured with the LSAS) and anxiety symptoms (measured with the STAI) in comparison to HC-participants. In addition, SAD-patients reported significantly more depressive symptoms than HC-participants as measured with the BDI. It should, however, be noted that the degree of reported depression symptoms in the SAD-patients indicates only minimal depression (mean ± standard deviation: 13.8 ± 8.8) ([@bb0045]), whereas the mean scores on the LSAS for the SAD-patients (mean ± standard deviation: 77.9 ± 17.9) are in line with a clinical diagnosis of SAD ([@bb0295]).Table 3Demographic and clinical characteristics of social anxiety disorder (SAD)-patients and healthy control (HC) participantsTable 3SAD (*n* = 174)HC (*n* = 213)Statistical analysisMeanSDMeanSD*p*Age (years)30.610.032.410.50.13Independent Samples\
Mann-Whitney *U* testAge of onset (years)[a](#tf0005){ref-type="table-fn"}14.87.1  SAD (*n* = 174)HC (*n* = 213)Statistical analysis*n*%*n*%*p*Males7241.49745.50.41χ^2^ testEducation level[b](#tf0010){ref-type="table-fn"}0.10χ^2^ test Low10.763.2 Intermediate5636.85429.0 High9562.512667.7Right-handed17298.920696.70.17χ2 TestComorbidity SAD only11465.5 SAD + MDD84.6 SAD + MDD + PD21.1 SAD + GAD105.7 SAD + GAD + SP31.7 SAD + GAD + PD21.1 SAD + PD31.7 SAD + SP63.4 Unknown2614.9Medication use at time of scan[c](#tf0015){ref-type="table-fn"}2414.2 SSRI17 Betablocker2 Antidepressivum NOS4 Unknown medication1  SAD (*n* = 174)HC (*n* = 213)Statistical analysisMeanSDMeanSD*p*Liebowitz Social Anxiety Scale (LSAS)[d](#tf0020){ref-type="table-fn"}77.917.914.312.6**\<0.001**Independent Samples\
Mann-Whitney U testBeck Depression Inventory (BDI)[e](#tf0025){ref-type="table-fn"}13.88.82.33.2**\<0.001**Independent Samples\
Mann-Whitney U testState-Trait Anxiety Inventory - State score[f](#tf0030){ref-type="table-fn"}43.210.120.911.0**\<0.001**Independent Samples\
*T*-TestState-Trait Anxiety Inventory - Trait score[f](#tf0030){ref-type="table-fn"}50.110.222.611.5**\<0.001**Independent Samples\
T-TestTotal Gray Matter Volume (mL)519.349.9522.358.70.47Independent Samples\
Mann-Whitney U test[^6][^7][^8][^9][^10][^11][^12]

3.2. ROI analyses: differences between SAD-patients and HC-participants {#s0045}
-----------------------------------------------------------------------

There was an effect of diagnosis in the basal ganglia ROI: SAD-patients had larger GM volume in the right putamen, extending into the pallidum ([Fig. 1](#f0005){ref-type="fig"}A and B; extent = 78 voxels, peak coordinate in MNI space: X = 26, Y = − 8, Z = 0; *p* = 0.022, small-volume corrected; result did not survive correction when all ROIs were taken together), with a small effect size (β = 0.14, Cohen\'s d = 0.20). A subsequent analysis, that regressed social anxiety symptoms within the SAD-patients on individual extracted GM volume in this region, revealed a significant positive correlation with a small effect size (zero-order correlation: Spearman\'s rho = 0.21, *p* = 0.010; multiple regression analysis while controlling for scan center, gender, age and total GM volume: β = 0.13, *p* = 0.048; see also [Fig. 1](#f0005){ref-type="fig"}C).Fig. 1**(A)** Larger GM volume in social anxiety disorder (SAD)-patients (*n* = 174) relative to healthy control (HC)-participants (*n* = 213) in the right dorsal striatum (*p* \< 0.05, small-volume corrected). **(B)** Dot density plot illustrating the group difference in GM volume in the dorsal striatum. **(C)** Scatterplot illustrating the relationship between social anxiety symptoms in a subset of SAD-patients (*n* = 148; measured with the Liebowitz Social Anxiety Scale, LSAS) and GM volume in the dorsal striatum (Spearman\'s rho = 0.21, *p* \< 0.05).Fig. 1

Given the fact that SAD often co-occurs with major depressive disorder (MDD) ([@bb0410]), we investigated whether the GM difference in the putamen was influenced by comorbid depression, by performing three subsequent analyses. Firstly, we excluded SAD-patients with a diagnosis of comorbid MDD (excluded: *n* = 10 SAD-patients; Table 3) and performed a multiple regression analysis with individual GM volume of the right putamen cluster as dependent variable, and diagnosis as independent variable while controlling for scan center, age, gender and total GM volume (remaining sample: *n* = 164 SAD-patients and 213 HC-participants). This analysis still showed a significant effect of diagnosis (β = 0.14, *p* = 0.002). Secondly, we excluded participants with a BDI score ≥ 30, indicating severe depression ([@bb0045]), (excluded: *n* = 7 SAD-patients; remaining sample: *n* = 106 SAD-patients and 111 HC-participants). Again, the effect of diagnosis was significant (β = 0.14, *p* = 0.017). In the third analysis, we examined the relationship between BDI-score and GM volume in the SAD-group (*n* = 113 SAD-patients; regression analysis, controlling for scan center, age, gender, and total GM volume). This analysis revealed a significant effect of BDI-score on GM volume (β = 0.17, *p* = 0.034). Importantly, when LSAS-score and BDI-score were both entered in the regression model, the effect of BDI was not significant anymore (β = 0.13, *p* = 0.13), while LSAS-score was still a significant predictor of GM volume (β = 0.16, *p* = 0.049). These results indicate that variation in BDI-scores in the SAD-sample did not significantly account for GM variance in the putamen-pallidum over and above effects of LSAS.

However, when we performed two additional sensitivity analyses to investigate the effect of 1^st^ general comorbidity and 2^nd^ medication use on the GM difference in the putamen, using multiple regression analyses with individual GM volume of the right putamen cluster as dependent variable, and diagnosis as independent variable while controlling for scan center, age, gender and total GM volume, the effect of diagnosis lacked significance (sensitivity analysis 1, including only SAD-patients without comorbidity: remaining sample: *n* = 114 SAD-patients and 213 HC-participants; β = 0.06, *p* = 0.28; sensitivity analysis 2, including only SAD-patients without present medication use: remaining sample: *n* = 59 SAD-patients and 117 HC-participants; β = 0.13, *p* = 0.13).

There were no clusters in the basal ganglia ROI where HC-participants had larger GM volume relative to SAD-patients. In addition, we did not find significant group-differences in the other ROIs using the VBM approach. To explore these null-findings, we extracted the individual GM volumes from the regions within each of the larger ROIs tested and examined the presence of between-group differences using multiple regression analyses controlled for scan center, age, gender and total GM volume. Because of the exploratory nature of these analyses, we corrected for the number of tests using Bonferroni-correction (13 regions, *p* ≤ 0.004). There were no regions in which the effect of diagnosis was significant at this Bonferroni-corrected significance level ([Inline Supplementary Table 2](#ec0015){ref-type="supplementary-material"}), although two effects were significant at the uncorrected level. Furthermore, we explored the possibility that these null-findings were present due to gender differences between patients, by investigating gender x diagnosis interactions. Again, no significant interactions were found at the Bonferroni-corrected significance level (*p* ≤ 0.004) (see [Inline Supplementary Table 2](#ec0015){ref-type="supplementary-material"}).

3.3. Whole-brain analysis: no group-differences {#s0050}
-----------------------------------------------

The exploratory whole-brain VBM analysis did not reveal a significant main effect of diagnosis. Significant diagnosis-by-age or diagnosis-by-scan center interactions were also not observed at whole-brain level.

4. Discussion {#s0055}
=============

In this study we investigated differences in GM volume between SAD-patients and HC-participants, in the largest sample of 3T structural MRI scans available for analysis to date (*n* = 174 SAD-patients and 213 HC-participants). We used a hypothesis-driven ROI approach and focused on differences in GM volume in the amygdala-hippocampal complex, the basal ganglia, the prefrontal cortex and parietal areas. The results showed larger GM volume in the right putamen in SAD-patients in comparison to HC-participants ([Fig. 1](#f0005){ref-type="fig"}A and B), and this increase in GM was positively correlated with the total score on the Liebowitz Social Anxiety Scale (LSAS) within the patient group ([Fig. 1](#f0005){ref-type="fig"}C). This effect remained significant when we performed several sensitivity analyses examining the effect of comorbid depression; however, the effect did not survive in two other sensitivity analyses in which patients with any type of comorbidity and medication use were excluded, possibly due to the fact that the remaining sample size was relatively small.

We did, however, not find diagnosis-related alterations in GM volumes in the amygdala-hippocampal, prefrontal or parietal ROIs. Furthermore, there were no group differences in an exploratory whole-brain analysis. To examine these results, we performed post-hoc analyses to examine group differences in individual structures of these ROIs, but again, no SAD-related GM differences were present ([Inline Supplementary Table 2](#ec0015){ref-type="supplementary-material"}). Furthermore, we checked whether GM differences between male and female SAD-patients might have confounded the results, but we did not find significant gender x diagnosis interactions ([Inline Supplementary Table 2](#ec0015){ref-type="supplementary-material"}).

4.1. No SAD-related changes in amygdala-hippocampal, prefrontal and parietal ROIs {#s0060}
---------------------------------------------------------------------------------

The null-findings in the amygdala-hippocampal, prefrontal and parietal ROIs were unexpected, because previous studies have reported SAD-related changes in GM in, among others, the amygdala, hippocampus, precuneus, prefrontal cortex and parietal regions ([@bb0075], [@bb0210], [@bb0205], [@bb0255], [@bb0260], [@bb0290], [@bb0420], [@bb0425], [@bb0455]). Although applying the usual caveats when interpreting null effects, our results based on the largest SAD-patient sample to date suggest that GM volume in regions outside the basal ganglia is likely not systematically related to SAD and thus might not underlie the alterations in brain functioning consistently reported and replicated in these regions ([@bb0070]). This idea is in line with the findings of a recent voxel-wise machine learning study, which suggested that SAD is easier to detect using multivariate analyses that take into account the global relationships between gray matter volume alterations in different regions than by applying analyses that only focus on local changes in specific brain regions ([@bb0135]).

With respect to the previous studies reporting SAD-related GM differences, it should be noted that the findings of these studies were often inconsistent, with increases as well as decreases in the same regions having been reported (e.g. for the amygdala, see [@bb0205], [@bb0260], [@bb0290]); see also [@bb0075] and [@bb0420] reporting no volumetric differences between SAD-patients and HC-participants, and [@bb0365], who did not observe changes in amygdalar GM volumes in a meta-analysis on structural neuroimaging findings across several anxiety disorders. These inconsistencies are most likely due to small sample sizes, which may have increased the probability of obtaining false-positive findings ([@bb0050], [@bb0080]) -- see also [@bb0100] for a critical overview of neuroimaging research findings in SAD. Furthermore, the inconsistencies are likely due to differences in methodology, for example the use of manual vs. automatic segmentation, the choice and size of ROIs, and to differences in clinical characteristics. Thus, the results of this study stress the need for studies with sufficient sample sizes and meta-analyses such as those performed by the Enhancing NeuroImaging Genetics through Meta-Analysis (ENIGMA) Consortium and its working groups ([@bb0040], [@bb0435]).

4.2. Larger GM volume in right putamen {#s0065}
--------------------------------------

We did find GM differences in the right putamen, which, together with the caudate, forms the dorsal striatum ([@bb0285]). The striatum is the major input structure of the basal ganglia, receiving information from the cortex, amygdala and hippocampus. The dorsal striatum is part of a network that is important for learning actions based on their predicted outcomes (i.e. reward-related behaviour), as well as for regulating cognitive and emotional behaviour ([@bb0285], [@bb0375], [@bb0400]); for a recent review on the role of the striatum in anxiety we refer to [@bb0235]. Interestingly, our findings converge with earlier research on the structural and functional basis of inhibited temperament, a characteristic that refers to the innate tendency to be shy, quiet and extremely cautious in novel social and non-social situations ([@bb0305]). Inhibited temperament substantially increases the risk for developing SAD ([@bb0085], [@bb0125]) and is correlated with larger volumes of both the amygdala and the caudate in young adults and hyperactivation in, among other areas, putamen, globus pallidus and caudate ([@bb0095], [@bb0090]) -- see [Inline Supplementary Table 3](#ec0020){ref-type="supplementary-material"} for coordinates of these and other findings discussed in this section. Moreover, Clauss and colleagues showed that the GM increase in the caudate was positively related to the level of activation in this area in response to neutral faces ([@bb0090]). Because larger GM volume of the caudate was also associated with increased functional connectivity to regions that respond to social stimuli, the authors have proposed that larger caudate volume might facilitate the saliency of social and novel stimuli for individuals with an inhibited temperament, which could predispose them for developing SAD ([@bb0090]). Combined with our observation that SAD is associated with larger GM volume in the putamen, it may be hypothesized that structural changes in the dorsal striatum, as an integral part of limbic circuitry ([@bb0400]), might underlie the biased processing of stimuli typically observed in SAD ([@bb0305]).

Evidence consistent with this idea comes from recent fMRI studies on SAD-related threat processing ([@bb0110], [@bb0190]). Anticipation of social punishment versus reward was associated with increased local activity in the putamen in SAD-patients compared to healthy controls. In addition, SAD-patients showed increased negative connectivity between the putamen and the ACC during social punishment and reward compared to HC-participants ([@bb0110]). Another study indicated that viewing ecologically valid, disorder-related complex visual scenes evoked increased activation in SAD-patients in, among others, the putamen and globus pallidus. Here, hyperactivation in the dorsal striatum was accompanied by increased connectivity with the amygdala, medial prefrontal cortex and ACC, regions playing an important role in emotion processing ([@bb0190]). These findings are supported by another resting-state study indicating hyperconnectivity of the putamen and the globus pallidus in SAD ([@bb0020]) and two meta-analyses on task-related activity in SAD, reporting increased activation of the globus pallidus ([@bb0160], [@bb0180]).

Additional support for our hypothesis comes from a within-subject longitudinal study on the neuro-anatomical effects of paroxetine in a small sample of fourteen patients with SAD, showing treatment-related decreases in symptom severity and concomitant reductions in GM in bilateral caudate and putamen ([@bb0430]). Furthermore, a 1H-magnetic resonance spectroscopy study demonstrated a relationship between social anxiety symptoms and the concentration of choline metabolites in the left caudate and right putamen ([@bb0195]), while single-photon emission computed tomography (SPECT) studies reported on alterations in the striatal dopaminergic system in patients with SAD ([@bb0360], [@bb0440], [@bb0460]), which are possibly related to striatal dysfunction ([@bb0350]). In addition, two recent PET studies indicated enhanced serotonin synthesis capacity in the striatum ([@bb0140], [@bb0145]). Given the role of serotonin in neuroplasticity and brain circuit development ([@bb0250]), concomitant brain structure alterations may be expected in this region. Combined with these previous findings, our results support the idea stated before ([@bb0070], [@bb0160]), that SAD-related changes in brain function and structure may be found outside the traditional fear circuitry, consisting of the amygdala, insula, prefrontal cortex and anterior cingulate cortex ([@bb0115]).

Notwithstanding the results of the present study, it should be noted that, despite the use of the largest database of structural MRI scans of SAD-patients available to date, the effect sizes obtained in our study were small (see [Fig. 2](#f0010){ref-type="fig"} for an illustration of the relationship between effect size and the power to detect an effect, given the sample size of our study). However, small effect sizes are not uncommon for studies on structural brain abnormalities in mental disorders ([@bb0200]); we refer the reader to the recent viewpoint articles by [@bb0050] and [@bb0340] for important insights on improving the validity and reproducibility of neuroimaging studies in psychiatry. Furthermore, because of the hypothesis-driven ROI approach, we did not correct the *p*-value for the number of ROIs tested. In addition, it should be mentioned that the GM increase was present in a region with a low GM density (mean GM volume ± SD in significant cluster: SAD-patients: 0.12 ± 0.05; HC-participants 0.10 ± 0.05; see also [Fig. 1](#f0005){ref-type="fig"}B). Together with the fact that it is hard to link neuroimaging results showing changes in brain structure directly to underlying cellular and molecular mechanisms like synaptogenesis, neurogenesis and changes in neuronal morphology ([@bb0245], [@bb0465]), this finding underscores that more research is needed to understand how the macroscopic SAD-related GM increase relates to effects at the microscopic level. It is also unclear, given the correlational nature of this study, whether and how structural differences in the dorsal striatum might play a causal or compensatory role in the pathogenesis of SAD. This underscores the need for future longitudinal studies on SAD, as well as for experiments that incorporate the dorsal striatum in animal models of social anxiety (compare [@bb0125]).Fig. 2Illustration of relation between effect size and power to detect effect, given the current sample size (*n* = 174 SAD-patients and *n* = 213 HC-participants), calculated using <https://www.ai-therapy.com/psychology-statistics/power-calculator>.Fig. 2

4.3. Study limitations and future studies {#s0070}
-----------------------------------------

The present study has several limitations. First, data on medication use and comorbidity were not available for all participants ([Table 3](#t0015){ref-type="table"}). Furthermore, only the current use of medication and present comorbidity were known, so we could not exclude heterogeneity within the sample due to past medication-use or past comorbidity. Another possible source of heterogeneity within the sample arises from the fact that we pooled data from multiple research centers located in various countries, which could add confounding effects of, for example, ethnicity and differences in scanner settings. However, we do not believe that these potential confounds have substantially influenced our results, as we corrected for scan center within our statistical model and since we did not find any diagnosis-by-scan center effects.

In the present study, we have exclusively investigated SAD-related differences in GM volumes. Future studies on structural brain alterations should examine changes in other parameters of brain anatomy, like cortical thickness, white matter integrity, and the shape of brain structures. The latter is especially interesting, given the recent insight that the shape of the putamen exhibits moderate-to-high heritability ([@bb0150], [@bb0345]). This, together with the understanding that SAD is familial and moderately heritable ([@bb0215], [@bb0300], [@bb0355], [@bb0450]), raises the question whether putamen shape could be considered a candidate endophenotype of SAD (compare [@bb0035]) and it will be interesting to investigate this in future studies. In addition, it would be worthwhile to perform multivariate pattern analyses (MVPA) ([@bb0005], [@bb0325]) to examine whether it is possible to discriminate SAD-patients from HC-participants based on GM volumes -- see for example [@bb0135]. Together with ongoing work on the functional brain alterations, as well as with the results of PET studies on brain metabolism in SAD, these findings may aid in unraveling the neurobiological basis of this serious and disabling disorder.

5. Conclusions {#s0075}
==============

In summary, the results of the present mega-analysis of the largest database of SAD brain scans to date showed larger GM volume in the dorsal striatum in SAD, which correlated positively with the severity of self-reported social anxiety symptoms. Combined with previous work on inhibited temperament and imaging studies on SAD, our results suggest that the dorsal striatum may play a role in the biased processing of social stimuli that is characteristic of SAD psychopathology. Importantly, we could not replicate GM alterations in the amygdala, hippocampus, prefrontal cortex and precuneus, regions previously implicated in SAD in imaging studies with smaller sample sizes. We take these null-findings as an indication that large sample sizes and investigations such as the meta-analyses performed by the ENIGMA Consortium are necessary for the reliable detection of neuro-anatomical changes in SAD.

The following are the supplementary data related to this article.Inline Supplementary Document 1Details on in- and exclusion criteria for each site.Inline Supplementary Document 1Inline Supplementary Table 1Scans excluded based on comorbidity other than anxiety and/or MDD.Inline Supplementary Table 1Inline Supplementary Table 2Overview results multiple regression analyses individual regions.Inline Supplementary Table 2Inline Supplementary Table 3Coordinates of findings summarized in the [Discussion](#s0055){ref-type="sec"}.Inline Supplementary Table 3
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[^1]: J.M.B.H. and H.v.S. share first authorship.

[^2]: SAD: Social Anxiety Disorder patients; HC: healthy control participants.

[^3]: Other than depression or anxiety (SAD-patients only).

[^4]: Insufficient scan-quality: scans with motion artefacts, scans being unsegmentable or scans for which brain extraction failed after multiple attempts.

[^5]: No data from HC-participants to balance design.

[^6]: GAD: generalized anxiety disorder; MDD: Major Depressive Disorder; NOS: not otherwise specified; PD: panic disorder; SP: specific phobia; SSRI: selective serotonin reuptake inhibitor

[^7]: Data from 65 SAD-patients.

[^8]: Data from 152 SAD-patients and 186 HC-participants.

[^9]: Data from 169 SAD-patients.

[^10]: Data from 148 SAD-patients and 140 HC-participants.

[^11]: Data from 113 SAD-patients and 111 HC-participants.

[^12]: Data from 75 SAD-patients and 73 HC-participants.
